Upper Tract Urothelial Carcinoma
Advertisement
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
Older patients over 70 years of age need improved care and management of UTUC to improve their outcomes.
Patients who had initiated AC 90 days after RNU were examined to determine a relation between treatment efficacy and timing.
Dr. Surena F. Matin shared valuable insights on lymph node dissection and kidney-sparing management for UTUC.
Dr. Katie S. Murray provided insight into identifying candidates for kidney-sparing management of upper tract disease.
The implications of VH have been thoroughly studied in bladder cancer, but further investigation is needed in UTUC.
Does the OLYMPUS trial have practice-changing potential for patients with low-grade, low-volume UTUC?
Breaking down kidney-sparing management for UTUC, ideal patients, and SOC for endoscopic resection or ureter resection.
Data supporting lymph node dissection at time of surgery for UTUC, as well as the risk factors for individual patients.
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.
ICIs for upper tract disease after upfront chemotherapy, along with the emerging role of targeted therapies.
Approaching perioperative systemic therapy in upper and lower tract disease, including neoadjuvant and adjuvant therapy.
The recently released AUA/SUO guideline on UTUC includes 6 guidelines on neoadjuvant/adjuvant chemotherapy and immunotherapy.
Assessing the treatment landscape in UTUC and how many different patient biomarkers influence treatment integration.
A continuation of the discussion on UTUC vascular-targeted photodynamic therapy as a way of nephron-sparing for patients.
Breaking down the differences in "high risk" and "low risk" stratification in the UTUC guideline, and other biomarkers.
A summary of the therapeutic strategies available for avoiding surgery for UTUC, as well as other management considerations.
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
There are 7 recommendations specific to the appropriateness of and proper technique for kidney-sparing management.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.